This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rohde, V. Articles by Wullich, B. Search for Related Content PubMed PubMed Citation Articles by Rohde, V. Articles by Wullich, B.

Expression of the Human Telomerase Reverse Transcriptase Is Not Related to Telomerase Activity in Normal and Malignant Renal Tissue¹

Clinic of Urology and Pediatric Urology [V. R., H-P. S., T. B., G. U., M. S., B. W.], Institute of Human Genetics [C. B., R. L.], and Institute of Pathology [H. B., T. F.], University of the Saarland, D-66421 Homburg/Saar, Germany

In this study, the association between telomerase activity and the expression of the human telomerase subunits human telomerase RNA (hTR) and human telomerase reverse transcriptase (hTERT) in paired neoplastic and normal renal tissue samples was investigated. Reverse transcription (RT)-PCR on 20 tumor nephrectomy samples revealed that hTR was constitutively expressed both in cancer and normal tissue samples, independent of the telomerase activity status. Remarkably, using in situ hybridization, the expression levels of hTR were found to be markedly higher in the normal tissue than those in the tumors. Expression of hTERT mRNA by RT-PCR was observed in 90% of the cancer samples and, notably, also in 75% of the corresponding normal renal tissue samples. Because all of the normal tissue samples and some of the tumor samples were shown to be telomerase negative, our findings suggest that hTERT mRNA expression is not sufficient for telomerase enzyme activation. Furthermore, semiquantitative RT-PCR revealed equal or even higher hTERT mRNA expression levels in the telomerase-negative normal samples than in the corresponding cancer samples with telomerase activity, contradicting the assumption that a certain threshold level of hTERT mRNA is required for telomerase activation at least in renal tissue. It seems more likely, that other mechanisms, such as posttranscriptional modification of hTERT or inactivation of telomerase inhibitors, are involved in the acquisition of enzyme activity.

This article has been cited by other articles:

				Y.-L. Wu, C. Dudognon, E. Nguyen, J. Hillion, F. Pendino, I. Tarkanyi, J. Aradi, M. Lanotte, J.-H. Tong, G.-Q. Chen, et al. Immunodetection of human telomerase reverse-transcriptase (hTERT) re-appraised: nucleolin and telomerase cross paths J. Cell Sci., July 1, 2006; 119(13): 2797 - 2806. [Abstract] [Full Text] [PDF]

				Y. Fan, Z. Liu, X. Fang, Z. Ge, N. Ge, Y. Jia, P. Sun, F. Lou, M. Bjorkholm, A. Gruber, et al. Differential Expression of Full-length Telomerase Reverse Transcriptase mRNA and Telomerase Activity between Normal and Malignant Renal Tissues Clin. Cancer Res., June 15, 2005; 11(12): 4331 - 4337. [Abstract] [Full Text] [PDF]

				Y.-S. Cong, W. E. Wright, and J. W. Shay Human Telomerase and Its Regulation Microbiol. Mol. Biol. Rev., September 1, 2002; 66(3): 407 - 425. [Abstract] [Full Text] [PDF]

				W. C. Hahn Telomerase and Cancer: Where and When? Clin. Cancer Res., October 1, 2001; 7(10): 2953 - 2954. [Full Text] [PDF]